Compare Symbotic Inc (SYM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs TransMedics Group Inc — how do they compare? Symbotic Inc trades at $42.3 (market cap $5.62B), while TransMedics Group Inc trades at $79.33 (market cap $2.81B). The key difference: Symbotic Inc is far larger — about 2× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Symbotic Inc for 23 Days and TransMedics Group Inc for 24 Days on average.
| SYM | TMDX | |
|---|---|---|
Market Cap | $5.62B | $2.81B |
Volume | 1,339,679 | 962,415 |
Sector | Industrials | Health |
52-Week High | $87.30 | $150.42 |
52-Week Low | $38.22 | $61.99 |
Typical Hold Time | 23 Days | 24 Days |
Enterprise Value | $3.88B | $3.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth potential with a $22.5 billion backlog but faces profitability challenges with negative net income of -$16.94 million in 2025. Analyst consensus is positive with a $60.33 price target, though recent earnings misses and customer concentration risk remain concerns.
SYM presents a growth opportunity in warehouse automation with significant backlog and expanding market demand, but investors must weigh high valuation multiples against current profitability issues and execution risks. The stock's upside depends on successful margin expansion and diversification beyond its major customer relationship.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
